Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: A three yearsâ following-up study
Clinical Rheumatology Aug 11, 2017
Zhao M, et al. – An observational study was conducted to evaluate the recurrence probability and the possible predictors in patients with ankylosing spondylitis (AS) from etanercept discontinuation. In AS patients who achieved the ASAS 20 response after receiving the treatment, no association was observed between the time of relapse and the duration of the treatment with etanercept. In addition, the older age and younger onset age of patients appeared to be important factors associated with an increased risk of relapse.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries